In two Phase 3 trials, Novartis’s remibrutinib reduced annualized relapse rates in relapsing multiple sclerosis by 35.2% and 31.2% versus Sanofi’s Aubagio—about one relapse every 13 years. Roche’s fenebrutinib exceeded 50%, but remibrutinib had a cleaner safety profile.